Introduction

Advances in surgical technique (1) and preoperative therapy (2,3) have made a significant impact in reducing postoperative positive margins and local recurrences in rectal cancer. Patients may still have positive resection margins resulting in an overall local recurrence rate between 5–15% (1,3,4) and a poorer overall survival rate (5) making resection margin status an important prognostic factor. After neoadjuvant radiation, it is unclear what the best local therapy approach for positive margin is after surgery for rectal cancer. Further surgery at recurrence may often not be feasible and have excessive morbidity (6,7). Additional external beam radiation therapy (EBRT) can be unsafe as dose limiting normal tissues in pelvis such as the bowel or the bladder have often been treated to tolerance (8). Intraoperative radiation therapy (IORT) (9) and brachytherapy (10) has been used when positive margins

Original Article

Post operative stereotactic radiosurgery for positive or close margins after preoperative chemoradiation and surgery for rectal cancer

Nergiz Dagoglu1, Elena Nedea2, Vitaliy Poylin3, Deborah Nagle3, Anand Mahadevan2

1Department of Radiation Oncology, Istanbul University, Istanbul, Turkey; 2Radiation Oncology, 3Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA

Contributions: (I) Conception and design: N Dagoglu, A Mahadevan; (II) Administrative support: None; (III) Provision of study materials or patients: V Poylin, D Nagle; (IV) Collection and assembly of data: D Nagle, A Mahadevan; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Anand Mahadevan, MD. Department of Radiation Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA. Email: amahadev@bidmc.harvard.edu.

Background: The incidence of positive margins after neoadjuvant chemoradiation and adequate surgery is very low. However, when patients do present with positive or close margins, they are at a risk of local failure and local therapy options are limited. We evaluated the role of stereotactic body radiotherapy (SBRT) in patients with positive or close margins after induction chemoradiation and total mesorectal excision.

Methods: This is a retrospective evaluation of patients treated with SBRT after induction chemoradiation and surgery for positive or close margins. Seven evaluable patients were included. Fiducial seeds were placed at surgery. The Cyberknife™ system was used for planning and treatment. Patients were followed 1 month after treatment and 3–6 months thereafter. Descriptive statistics and Kaplan-Meier method was used to report the findings.

Results: Seven patients (3 men and 4 women) were included in the study with a median follow-up of 23.5 months. The median initial radiation dose was 5,040 cGy (in 28 fractions) and the median SBRT dose was 2,500 cGy (in 5 fractions). The local control at 2 years was 100%. The overall survival at 1 and 2 years was 100% and 71% respectively. There was no Grade III or IV toxicity.

Conclusions: SBRT reirradiation is an effective and safe method to address positive or close margins after neoadjuvant chemoradiation and surgery for rectal cancer.

Keywords: Stereotactic body radiotherapy (SBRT); positive margin; reirradiation

Submitted Sep 12, 2015. Accepted for publication Sep 30, 2015.
doi: 10.21037/jgo.2015.11.03
View this article at: http://dx.doi.org/10.21037/jgo.2015.11.03
are anticipated at the time of surgery, but often microscopic positive margins are unsuspected.

Stereotactic Body Radiotherapy (SBRT) has been successfully used in the primary therapy or as a boost due to its conformality and sharp dose fall off thereby avoiding dose limiting normal structures of normal structures (11,12). Hence it is conceivable that SBRT may be applicable for positive margins in patients with rectal cancer who have had neoadjuvant radiation. We report our experience in the use of SBRT as a boost to positive margins after prior radiation.

Methods

Patients and lesions

Our institutional IRB approved database (DFHCC 09-451) was retrospectively reviewed. Rectal carcinoma patients previously treated with radiation, with positive margins after surgery, who were treated with SBRT, were included in this study. Seven patients were identified between February 2006 and December 2012.

SBRT treatment

At least three gold fiducial markers were placed at the area of concern during surgery. All patients underwent CT simulation in supine position with VacLoc™ body immobilization system. Intravenous and rectal barium contrast agent was used during CT planning and 1 mm axial CT images were obtained in the region of interest. The gross tumor volume (GTV) and was contoured on axial CT images. The Multiplan™ software was used for treatment planning and all patients were treated with the Cyberknife™ system with real time fiducial tracking. The pathology report was correlated with the fiducial markers to identify the target volume. The dose fractionation scheme was individualized based mostly on tumor volume and location of the tumor. Other factors, such as, patients’ performance and comorbidity were also taken into consideration.

Close/positive margins

For this study positive margin was described as being ≤1 mm and close margins was defined as cancer cells within 1–2 mm.

Follow-up

Follow-up data included status of disease, date of progression if any, site of failure and last follow up date. Routine follow-up included CT imaging at 1 month after treatment and 3–6 months thereafter. Local failure was defined as clinical or radiological evidence of pelvic recurrence. If a new lesion developed in the pelvis but outside the radiation field, it was interpreted as failure outside the treated area. Acute and late toxicities were defined as symptoms that develop within three months after SBRT or later, respectively.

Statistics

Descriptive statistics was used to describe the data. Kaplan-Meir actuarial curves were used to estimate local control and overall survival. GraphPad Prism Version 6.0.c software (GraphPad Software, Inc., La Jolla, CA, USA) was used for statistical analysis.

Results

Pretreatment characteristics

Seven patients were treated with SBRT boost with the Cyberknife™ system for positive margins at our center between February 2006 and December 2012. Three males and four females were included. The median age at the time of reirradiation was 65 years (range, 48–79 years).

Initial stages at presentation were as follows: T4N1 in one patient, T4N0 in one patient, T3N2 in four patients and T3N0 in two patients. As initial surgery, four patients underwent abdomino-perineal resection (APR), three had low anterior resection (LAR). All patients had previously received EBRT, six as part of neoadjuvant therapy and one patient had pelvic irradiation for endometrial cancer before she was diagnosed with rectal cancer. For the eight lesions treated the prior radiation dose received was 50.4 Gy. The patient characteristics are described in Table 1.

SBRT treatment

The median tumor volume was 84.96 cc (range, 68.27–212.91 cc). The median prescription isodose was 78% (range, 69–86%). Total SBRT dose ranged from 10 to 25 Gy (median 25 Gy) in fractions ranging from 1 to 5 (median 5). Median conformity index (CI) and homogeneity index (HI) was 1.23 and 1.32 respectively. The treatment characteristics are described in Table 2. A representative treatment plan is shown in Figure 1.
Efficacy

Median follow-up from the time of SBRT was 23.5 months (18.4 to 101.8 months). The actuarial 1- and 2-year survival rates were 100%, 71% respectively. The long-term local control rates were 100%. Local progression free survival rates at 1 and 2 year were 71% and 57% respectively. The follow-up data is also summarized in Table 1. Actuarial local control, progression free survival and overall survival are shown in Figure 2.

Toxicity

Most patients (6 out of 7) developed fatigue. Two patients had diarrhea, which was controlled with medication not
requiring further treatment.

**Discussion**

Fortunately, neoadjuvant radiation and chemoradiation and improved surgical techniques have significantly decreased the likelihood of positive margins. However, when they do occur in 5-15% of patients, it can be a therapeutic challenge. We have shown in this series that planned SBRT can be a safe and useful technique to salvage positive margins after neoadjuvant chemoradiation and surgery. In our case series of seven patients who had SBRT treatments for positive margins, we observed a 100% local control for long term and overall survival of 100% in 1 year and 71% in 2 year, with only Grade II toxicity.

It is well known that positive margins after surgery is a poor prognostic factor for local recurrence and survival (5,13). With upfront surgery, postoperative chemoradiation is often used to in patients with positive margins (14) to improve local control and survival. However in the setting of neoadjuvant chemoradiation, the significance of a positive margin is unclear and the management can be challenging. When patients are at a high risk for positive margins, in the locally advanced or recurrent setting, traditionally IORT (15) and brachytherapy (10) has been used. Even if these techniques are available, often-microscopic margins are not anticipated until full pathological review. Notwithstanding, apart from technical challenges, IORT and brachytherapy are not without significant toxicity (16,17). Conventional external beam radiation in this setting is often limited by tolerance to previously radiated pelvic tissues, particularly bowel.

Salvage after pelvic failure can be formidable, particularly after prior radiation therapy. More often after initial combined modality therapy, pelvic failures are salvaged by further surgery (18,19) with or without further radiation (20). However this is often not feasible without exenteration (21) and is associated with significant morbidity (16,17). IORT, brachytherapy, described above, and carbon ion therapy (22) have been used, but they are limited by availability and toxicity. Hence it makes sound clinical sense to prevent pelvic recurrences in the setting of positive margins after neoadjuvant chemoradiation and surgery.

SBRT has been used in the setting of pelvic recurrences after prior radiation (23-25). While these studies have shown that SBRT can be done safely, it is not curative in...
the treatment of gross recurrence. Hence we utilized SBRT electively to prevent pelvic failures in patients who had positive margins after neoadjuvant chemoradiation and surgery. This is a small retrospective series showing safety and efficacy of SBRT boost for positive margins after prior pelvic radiation, and further prospective studies need to be done to evaluate this approach.

Conclusions

After neoadjuvant chemoradiation and surgery close or positive microscopic margins can potentially lead to pelvic failure. Salvage may not be curative and associated with toxicity. In this first report of its kind, we have shown SBRT in this setting can safely decrease the likelihood of pelvic failure.

Acknowledgements

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References


Cite this article as: Dagoglu N, Nedea E, Poylin V, Nagle D, Mahadevan A. Post operative stereotactic radiosurgery for positive or close margins after preoperative chemoradiation and surgery for rectal cancer. J Gastrointest Oncol 2016;7(3):315-320. doi: 10.21037/jgo.2015.11.03